ALRN-6924, Clinical Trials, T-Cell Lymphoma

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

This study is currently recruiting participants.

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53

Study Type:        Interventional

Study Design:        

Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Official Title:        A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein                                                         

Condition: Peripheral T-Cell Lymphoma 
                          Solid Tumor
                          Lymphoma                                    

Intervention:  

Drug: ALRN-6924 
                           

Phase:  Phase 1
                 Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT02264613